Economic evaluation of hemodialysis: Implications for technology assessment in Greece

被引:34
|
作者
Kaitelidou, D
Ziroyanis, PN
Maniadakis, N
Liaropoulos, LL
机构
[1] Univ Athens, Ctr Hlth Serv Management & Evaluat, Dept Nursing, Athens 11527, Greece
[2] G Gennimatas Hosp, Dept Nephrol, Athens 11527, Greece
[3] Univ Hosp Rio, Rio Patra 26504, Greece
关键词
cost of hemodialysis; economic evaluation; cost of illness;
D O I
10.1017/S0266462305050051
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: Hemodialysis is a well-established treatment for 74 percent of end-stage renal disease (ESRD) patients in Greece. The purpose of this study is to provide an estimate of the direct cost of dialysis in a public hospital setting and an estimate of the loss of production for ESRD patients. The results will be useful for public health facility planning purposes. Methods: A socioeconomic prevalence-based analysis was performed using micro-economic evaluation of health-care resources consumed to provide hemodialysis for ESRD patients in 2000. Lost productivity costs due to illness were estimated for the patient and family using the human capital approach and the friction method. Indirect morbidity costs due to absence from work and long-term were estimated, as well as mortality costs. Mean gross income was used for both patient and family. Results: Total health-sector cost for hemodialysis in Greece exceeds Euro 171 million, or Euro 182 per session and Euro 229 per inpatient day. There were 2,046 years lost due to mortality, and the potential productivity cost was estimated at Euro 9.9 million, according to the human capital approach, and Euro 303.000, according to the friction method. Total morbidity cost due to absence from work and early retirement was estimated at more than Euro 273 million, according to the human capital approach, and Euro 12.5, according to the friction method. Conclusions: Providing hemodialysis care for 0.05 percent of the population suffering from ESRD absorbs approximately 2 percent of total health expenditure in Greece. In addition to the cost for the National Health System, production loss due to mortality and morbidity from the disease are also considerable. Promoting alternative technologies such as organ transplantation and home dialysis as well as improving hemodialysis efficiency through satellite units are strategies that may prove more cost-effective and psychologically advantageous for the patients.
引用
收藏
页码:40 / 46
页数:7
相关论文
共 50 条
  • [21] Chatbot Technology Assessment: 40 Cases from Greece
    Charalabidis, Yannis
    Anagnou, Thanos
    Alexopoulos, Charalampos
    Papadopoulos, Theodoros
    Lachana, Zoi
    Bouras, Christos
    Karacapilidis, Nikos
    Kokkinos, Vasileios
    Gkamas, Apostolos
    INFORMATION SYSTEMS, PT 1, EMCIS 2023, 2024, 501 : 167 - 181
  • [22] CURRENT ENVIRONMENT FOR INTRODUCING HEALTH TECHNOLOGY ASSESSMENT IN GREECE
    Kani, Chara
    Kourafalos, Vasilios
    Litsa, Panagiota
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2017, 33 (03) : 396 - 401
  • [23] HELSPOR'S ASSESSMENT OF THE PHARMACEUTICAL POLICY REFORMS IN GREECE: COST-CONTAINMENT AND ECONOMIC EVALUATION CRITERIA
    Kousoulakou, H.
    Papanicolaou, S.
    Geitona, M.
    VALUE IN HEALTH, 2009, 12 (07) : A239 - A239
  • [24] Limitations of traditional health technology assessment methods and implications for the evaluation of novel therapies
    Doctor, Jason
    MacEwan, Joanna P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (09) : 1635 - 1642
  • [25] ECONOMIC EVALUATION OF LANREOTIDE AUTOGEL IN THE MANAGEMENT OF ACROMEGALY IN GREECE
    Kousoulakou, H.
    Panayiotou-Pazaitou, K.
    Pantazi, E.
    Tsentidis, C.
    Tzanela, M.
    Vryonidou, A.
    Markussis, V
    Eleftheriou, C.
    Geitona, M.
    VALUE IN HEALTH, 2014, 17 (07) : A348 - A349
  • [26] Economic evaluation of various anti hypertensive monotherapies in Greece
    Stafilas, PC
    Zouka, MD
    Sarafidis, PA
    Lasaridis, AN
    Aletras, VH
    VALUE IN HEALTH, 2004, 7 (06) : 691 - 691
  • [27] ECONOMIC EVALUATION OF NALMEFENE FOR THE TREATMENT OF ALCOHOL DEPENDENCE IN GREECE
    Relakis, J.
    Paparrigopoulos, T.
    Kourlaba, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2014, 17 (07) : A458 - A458
  • [28] ECONOMIC EVALUATION OF OPIOID SUBSTITUTION TREATMENT (OST) IN GREECE
    Geitona, M.
    Carayanni, V
    Petratos, P.
    Androutsou, L.
    VALUE IN HEALTH, 2012, 15 (07) : A512 - A512
  • [29] Economic evaluation of tiotropium and salmeterol in the treatment of COPD in Greece
    Maniadakis, N
    Tzanakis, N
    Geitona, M
    Fragoulakis, V
    Hatzikou, M
    Siafakas, N
    VALUE IN HEALTH, 2005, 8 (06) : A213 - A213
  • [30] Economic policies in Greece during 1990-1993: An assessment
    Pelagidis, T
    JOURNAL OF MODERN GREEK STUDIES, 1997, 15 (01) : 67 - 85